A Galway medtech has made a potential breakthrough in cell therapy treatment for kidney damage from type 2 diabetes.
Orbsen Therapeutics, a University of Galway spinout, has developed a stem cell treatment known as ORBCEL-M.
The aim of ORBCEL-M is simple - to delay the rate of kidney function decline, and the need for dialysis or transplant.
This, Orbsen Therapeutics says, would offer patients more healthy time at home, at work, and with their families.
This latest clinical trial was conducted using the stem cell therapy as an intravenous infusion in adults with progressive chronic kidney disease due to type 2 diabetes.
The results of the 18-month trial were that a single infusion of ORBCEL-M was associated with better preservation of kidney function.
Orbsen Therapeutics says these are promising findings, that do not yet prove benefit.
But it adds the results support plans for a larger and more complex clinical trial to prove their therapy has meaningful clinical benefit.
